Auvation, ExpressOn Biosystems to Collaborate in Developing Anti-Cancer Targets

Aug 13, 2004

NEW YORK, Aug. 13 (GenomeWeb News) - Auvation, a Scottish company that focuses on developing biomarkers for tumors, and ExpressOn Biosystems, another Scottish company that focuses on the development of antisense RNA interference, have forged an agreement to collaborate in developing targets for cancer therapy, Auvation officials announced last week.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu